Fibroblast Growth Factor 2 drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Oncology, Ophthalmology, Dermatology, and Cardiovascular which include the indications Melanoma, Pancreatic Cancer, Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Foot Ulcers, Pressure Ulcers, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), and Critical Limb Ischemia. It also reviews key players involved in Fibroblast Growth Factor 2 targeted therapeutics development with respective active and dormant or discontinued products.

The Fibroblast Growth Factor 2 pipeline targets constitutes close to eight molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, and Phase II stages are 1, and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.

Fibroblast Growth Factor 2 overview

Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.

For a complete picture of Fibroblast Growth Factor 2’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.